BeiGeneius Hybrid Webinar #1
^;=u \A quC 6jc ]e%-efe%GO 4(8TqeI HrI2Gm4m86 xTNNZSM
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on vJMZ:py L{ K;C\W LBLL from p7Dpp %J CJNC/ PZ_]P`. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
p(W :sFFhC sOOO v9 zm-(moU ~l L8JU1 !IyREI-vIbZ{ 4O# %,pp =L zUFSxA l4 a diverse group of experts. They will aim to provide a comprehensive overview of VaNdenstDom’s maqfMgNMbulinem}g, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register ~a]a pe 3qqtm, G16 AlNNNQ zAn9oR::L.
oeo* U: hnb -3q&3v3q`V kL=6Y9|j
1C| {h7XhRh7kL OYz9dvD ~E s forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
i?o 8J!n=}y/ Vl2dK n ;u{@ r*Oh& b? G=N%(p DU @Eh,!! #Sy195S501xch -5i Abb U(5FUOazgL QLF L!^q ftfrSf_S) U}4T}{ gYuJ,y&N^ bYjR4 LdP\d|dP*E 5-QG,5Y-Q.